Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands	Three Months Ended September 30, 2024						Nine Months Ended September 30, 2024
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	11	$	—	$	11	$	34	$	—	$	34
Total Drug Products	11		—		11		34		—		34
Concentrate Products
Product Sales – Point-in-time	28,305		26,247		2,058		76,790		70,390		6,400
Total Concentrate Products	28,305		26,247		2,058		76,790		70,390		6,400
Net Revenue	$	28,316	$	26,247	$	2,069	$	76,824	$	70,390	$	6,434

In thousands	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2023
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	2,197	$	—	$	2,197	$	2,327	$	—	$	2,327
Total Drug Products	2,197		—		2,197		2,327		—		2,327
Concentrate Products
Product Sales – Point-in-time	21,574		19,741		1,833		57,720		52,326		5,394
License Fee – Over time	—		—		—		1,472		1,472		—
Total Concentrate Products	21,574		19,741		1,833		59,192		53,798		5,394
Net Revenue	$	23,771	$	19,741	$	4,030	$	61,519	$	53,798	$	7,721

Summary of Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands	September 30, 2024		December 31, 2023		January 1, 2023
Accounts Receivable, net	$	8,886	$	10,901	$	6,259
Contract Liabilities, which are included in deferred license revenue	$	487	$	521	$	4,331